Weiss Ratings Reiterates “Sell (E+)” Rating for Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ:EVOK)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, September 7th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Evoke Pharma Trading Up 1.1%

Shares of EVOK opened at $4.76 on Wednesday. The firm has a market capitalization of $7.43 million, a P/E ratio of -1.86 and a beta of -0.10. Evoke Pharma has a 12-month low of $1.94 and a 12-month high of $12.32. The firm has a fifty day moving average price of $5.18 and a 200-day moving average price of $3.87.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Thursday, August 14th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.32). The company had revenue of $3.75 million for the quarter, compared to analysts’ expectations of $3.80 million. Evoke Pharma had a negative net margin of 42.07% and a negative return on equity of 99.48%.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.